製品の概要

製品の詳細

  • 由来Synthetic

関連製品

特性

Our Abpromise guarantee covers the use of ab107795 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • 精製度70 - 90% by HPLC.

  • 備考

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

関連情報

  • 別名
    • 4
    • 5-trisphosphate receptor
    • 5-trisphosphate receptor type 1
    • DKFZp313E1334
    • DKFZp313N1434
    • Inositol 1
    • inositol 1 4 5 triphosphate receptor type 1
    • Inositol 1 4 5 trisphosphate Receptor Type 1
    • InsP3R1
    • IP3
    • IP3 receptor
    • IP3 receptor isoform 1
    • IP3R
    • IP3R 1
    • IP3R1
    • ITPR 1
    • Itpr1
    • ITPR1_HUMAN
    • SCA15
    • SCA16
    • SCA29
    • Type 1 inositol 1
    • Type 1 inositol 1 4 5 trisphosphate receptor
    • Type 1 InsP3 receptor
    see all
  • 機能Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate.
  • 組織特異性Widely expressed.
  • 関連疾患Defects in ITPR1 are the cause of spinocerebellar ataxia type 15 (SCA15) (SCA15) [MIM:606658]. Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA15 is an autosomal dominant cerebellar ataxia (ADCA). It is very slow progressing form with a wide range of onset, ranging from childhood to adult. Most patients remain ambulatory.
  • 配列類似性Belongs to the InsP3 receptor family.
    Contains 5 MIR domains.
  • ドメインThe receptor contains a calcium channel in its C-terminal extremity. Its large N-terminal cytoplasmic region has the ligand-binding site in the N-terminus and modulatory sites in the middle portion immediately upstream of the channel region.
  • 翻訳後修飾Phosphorylated by cAMP kinase. Phosphorylation prevents the ligand-induced opening of the calcium channels.
    Phosphorylated on tyrosine residues.
  • 細胞内局在Endoplasmic reticulum membrane.
  • Information by UniProt

IP3 receptor peptide (ab107795) 使用論文

ab107795 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab107795.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"